April 29, 2022
SAN RAMON, Calif. – CooperVision will present new data and analysis about the performance and efficacy of MiSight 1 day contact lenses for slowing the progression of myopia during the 2022 Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver.
Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing (Meyer D, et al.) presents evidence that myopia control using MiSight 1 day contact lenses is achieved through added myopic defocus, validating prior hypotheses.1 The study also quantified the myopic defocus dose delivered to children in two ways: by diopters and by the proportion of light focused in front of the retina. This work was conducted with the Indiana University School of Optometry.
Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear (Hammond D, et al.) offers further in-depth analysis of the seven-year MiSight 1 day clinical trial, which is the longest-running soft contact lens study among children. CooperVision previously reported that twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained among the entire cohort.2, 3, Ɨ
This latest work provides a deeper dive into the year seven data. These results indicate that treatment effects are retained regardless of when treatment ceased at any age between 14 to 18. The investigators conclude that starting MiSight 1 day at a younger age and continuing throughout teenage years reduces time during which untreated eye growth can occur.4
“The works we are presenting at ARVO build further confidence in MiSight 1 day contact lenses* as a preferred approach,” said Paul Chamberlain, BSc (Hons), Director of Research Programs for CooperVision.
CooperVision’s additional ARVO 2022 research presentations, including advancements in contact lens comfort science and other topics, can be viewed at arvo.org/annual-meeting/.
Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval of MiSight® 1 day.
* U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
Ɨ Preliminary international study data show that, on average, for children who discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.
1 Meyer D, et al. Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing. ARVO 2022 poster presentation.
2 Chamberlain P, Arumugam B, et al. Myopia Progression on Cessation of Dual-Focus Contact Lens Wear: MiSight 1 day 7-Year Findings. Optom Vis Sci 2021;98:E-abstract 210049
3 Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with No Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130
4 Hammond D, et al. Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear. ARVO 2022 poster presentation.